TY - JOUR
T1 - Circulating Vitamin D and colorectal cancer risk
T2 - An international pooling project of 17 cohorts
AU - McCullough, Marjorie L.
AU - Zoltick, Emilie S.
AU - Weinstein, Stephanie J.
AU - Fedirko, Veronika
AU - Wang, Molin
AU - Cook, Nancy R.
AU - Eliassen, A. Heather
AU - Zeleniuch-Jacquotte, Anne
AU - Agnoli, Claudia
AU - Albanes, Demetrius
AU - Barnett, Matthew J.
AU - Buring, Julie E.
AU - Campbell, Peter T.
AU - Clendenen, Tess V.
AU - Freedman, Neal D.
AU - Gapstur, Susan M.
AU - Giovannucci, Edward L.
AU - Goodman, Gary G.
AU - Haiman, Christopher A.
AU - Ho, Gloria Y.F.
AU - Horst, Ronald L.
AU - Hou, Tao
AU - Huang, Wen Yi
AU - Jenab, Mazda
AU - Jones, Michael E.
AU - Joshu, Corinne E.
AU - Krogh, Vittorio
AU - Lee, I. Min
AU - Lee, Jung Eun
AU - Männistö, Satu
AU - Le Marchand, Loic
AU - Mondul, Alison M.
AU - Neuhouser, Marian L.
AU - Platz, Elizabeth A.
AU - Purdue, Mark P.
AU - Riboli, Elio
AU - Robsahm, Trude Eid
AU - Rohan, Thomas E.
AU - Sasazuki, Shizuka
AU - Schoemaker, Minouk J.
AU - Sieri, Sabina
AU - Stampfer, Meir J.
AU - Swerdlow, Anthony J.
AU - Thomson, Cynthia A.
AU - Tretli, Steinar
AU - Tsugane, Schoichiro
AU - Ursin, Giske
AU - Visvanathan, Kala
AU - White, Kami K.
AU - Wu, Kana
AU - Yaun, Shiaw Shyuan
AU - Zhang, Xuehong
AU - Willett, Walter C.
AU - Gail, Mitchel H.
AU - Ziegler, Regina G.
AU - Smith-Warner, Stephanie A.
N1 - Publisher Copyright:
© 2019 Oxford University Press. All rights reserved.
PY - 2019/2/1
Y1 - 2019/2/1
N2 - Background: Experimental and epidemiological studies suggest a protective role for vitamin D in colorectal carcinogenesis, but evidence is inconclusive. Circulating 25-hydroxyvitamin D (25(OH)D) concentrations that minimize risk are unknown. Current Institute of Medicine (IOM) vitamin D guidance is based solely on bone health. Methods: We pooled participant-level data from 17 cohorts, comprising 5706 colorectal cancer case participants and 7107 control participants with a wide range of circulating 25(OH)D concentrations. For 30.1% of participants, 25(OH)D was newly measured. Previously measured 25(OH)D was calibrated to the same assay to permit estimating risk by absolute concentrations. Study-specific relative risks (RRs) for prediagnostic season-standardized 25(OH)D concentrations were calculated using conditional logistic regression and pooled using random effects models. Results: Compared with the lower range of sufficiency for bone health (50-<62.5 nmol/L), deficient 25(OH)D (<30 nmol/L) was associated with 31% higher colorectal cancer risk (RR = 1.31, 95% confidence interval [CI] = 1.05 to 1.62); 25(OH)D above sufficiency (75-<87.5 and 87.5-<100 nmol/L) was associated with 19% (RR = 0.81, 95% CI = 0.67 to 0.99) and 27% (RR = 0.73, 95% CI = 0.59 to 0.91) lower risk, respectively. At 25(OH)D of 100 nmol/L or greater, risk did not continue to decline and was not statistically significantly reduced (RR = 0.91, 95% CI = 0.67 to 1.24, 3.5% of control participants). Associations were minimally affected when adjusting for body mass index, physical activity, or other risk factors. For each 25 nmol/L increment in circulating 25(OH)D, colorectal cancer risk was 19% lower in women (RR = 0.81, 95% CI = 0.75 to 0.87) and 7% lower in men (RR = 0.93, 95% CI = 0.86 to 1.00) (two-sided Pheterogeneitybysex = .008). Associations were inverse in all subgroups, including colorectal subsite, geographic region, and season of blood collection. Conclusions: Higher circulating 25(OH)D was related to a statistically significant, substantially lower colorectal cancer risk in women and non-statistically significant lower risk in men. Optimal 25(OH)D concentrations for colorectal cancer risk reduction, 75-100 nmol/L, appear higher than current IOM recommendations.
AB - Background: Experimental and epidemiological studies suggest a protective role for vitamin D in colorectal carcinogenesis, but evidence is inconclusive. Circulating 25-hydroxyvitamin D (25(OH)D) concentrations that minimize risk are unknown. Current Institute of Medicine (IOM) vitamin D guidance is based solely on bone health. Methods: We pooled participant-level data from 17 cohorts, comprising 5706 colorectal cancer case participants and 7107 control participants with a wide range of circulating 25(OH)D concentrations. For 30.1% of participants, 25(OH)D was newly measured. Previously measured 25(OH)D was calibrated to the same assay to permit estimating risk by absolute concentrations. Study-specific relative risks (RRs) for prediagnostic season-standardized 25(OH)D concentrations were calculated using conditional logistic regression and pooled using random effects models. Results: Compared with the lower range of sufficiency for bone health (50-<62.5 nmol/L), deficient 25(OH)D (<30 nmol/L) was associated with 31% higher colorectal cancer risk (RR = 1.31, 95% confidence interval [CI] = 1.05 to 1.62); 25(OH)D above sufficiency (75-<87.5 and 87.5-<100 nmol/L) was associated with 19% (RR = 0.81, 95% CI = 0.67 to 0.99) and 27% (RR = 0.73, 95% CI = 0.59 to 0.91) lower risk, respectively. At 25(OH)D of 100 nmol/L or greater, risk did not continue to decline and was not statistically significantly reduced (RR = 0.91, 95% CI = 0.67 to 1.24, 3.5% of control participants). Associations were minimally affected when adjusting for body mass index, physical activity, or other risk factors. For each 25 nmol/L increment in circulating 25(OH)D, colorectal cancer risk was 19% lower in women (RR = 0.81, 95% CI = 0.75 to 0.87) and 7% lower in men (RR = 0.93, 95% CI = 0.86 to 1.00) (two-sided Pheterogeneitybysex = .008). Associations were inverse in all subgroups, including colorectal subsite, geographic region, and season of blood collection. Conclusions: Higher circulating 25(OH)D was related to a statistically significant, substantially lower colorectal cancer risk in women and non-statistically significant lower risk in men. Optimal 25(OH)D concentrations for colorectal cancer risk reduction, 75-100 nmol/L, appear higher than current IOM recommendations.
UR - http://www.scopus.com/inward/record.url?scp=85060553019&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060553019&partnerID=8YFLogxK
U2 - 10.1093/jnci/djy087
DO - 10.1093/jnci/djy087
M3 - Article
C2 - 29912394
AN - SCOPUS:85060553019
SN - 0027-8874
VL - 111
SP - 158
EP - 169
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 2
ER -